RU2018139711A - Состояние воздержания от пищи в качестве диетического лечения диабета - Google Patents
Состояние воздержания от пищи в качестве диетического лечения диабета Download PDFInfo
- Publication number
- RU2018139711A RU2018139711A RU2018139711A RU2018139711A RU2018139711A RU 2018139711 A RU2018139711 A RU 2018139711A RU 2018139711 A RU2018139711 A RU 2018139711A RU 2018139711 A RU2018139711 A RU 2018139711A RU 2018139711 A RU2018139711 A RU 2018139711A
- Authority
- RU
- Russia
- Prior art keywords
- days
- diets
- per day
- vitamin
- day
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims 25
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000000378 dietary effect Effects 0.000 title 1
- 230000037213 diet Effects 0.000 claims 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 235000021084 monounsaturated fats Nutrition 0.000 claims 2
- 235000021085 polyunsaturated fats Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 235000021003 saturated fats Nutrition 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- 229930003537 Vitamin B3 Natural products 0.000 claims 1
- 229930003571 Vitamin B5 Natural products 0.000 claims 1
- 229930003761 Vitamin B9 Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims 1
- 229960002079 calcium pantothenate Drugs 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 235000020905 low-protein-diet Nutrition 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 235000019160 vitamin B3 Nutrition 0.000 claims 1
- 239000011708 vitamin B3 Substances 0.000 claims 1
- 235000009492 vitamin B5 Nutrition 0.000 claims 1
- 239000011675 vitamin B5 Substances 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 235000019159 vitamin B9 Nutrition 0.000 claims 1
- 239000011727 vitamin B9 Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pediatric Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
Claims (12)
1. Комплект диет для облегчения симптомов повреждения бета-клеток поджелудочной железы у субъекта, включающий:
рационы для назначения диеты, имитирующей воздержание от пищи, субъекту в течение первого периода времени, при этом диета, имитирующая воздержание от пищи, предусматривает от 4,5 до 7 килокалорий на фунт веса тела субъекта в первый день и от 3 до 5 килокалорий на фунт веса тела субъекта в день для дней со второго по пятый, причем диета, имитирующая воздержание от пищи, представляет собой низкобелковую диету, которая обеспечивает менее 28 г белков в первый день и менее 18 г белков для дней со второго по пятый.
2. Комплект диет по п. 1, где рационы обеспечивают менее 30 г сахара в первый день; менее 20 г сахара для дней со второго по пятый.
3. Комплект диет по п. 1, где рационы обеспечивают от 20 до 30 граммов мононенасыщенных жиров в первый день.
4. Комплект диет по п. 3, где рационы обеспечивают от 10 до 15 граммов мононенасыщенных жиров для дней со второго по пятый.
5. Комплект диет по п. 1, где рационы обеспечивают от 6 до 10 граммов полиненасыщенных жиров в первый день и от 3 до 5 граммов полиненасыщенных жиров для дней со второго по пятый.
6. Комплект диет по п. 1, где рационы обеспечивают менее 12 г насыщенных жиров в первый день и менее 6 грамм насыщенных жиров для дней со второго по пятый.
7. Комплект диет по п. 1, где рационы обеспечивают от 12 до 25 граммов глицерина в день для дней со второго по пятый.
8. Комплект диет по п. 1, где рационы обеспечивают более 5000 МЕ витамина А в день для дней 1-5 и 60-240 мг витамина C в день для дней 1-5.
9. Комплект диет по п. 8, где рационы обеспечивают 400-800 мг кальция в день для дней 1-5; 7,2-14,4 мг железа в день для дней 1-5; 200-400 мг магния в день для дней 1-5; 1-2 мг меди в день для дней 1-5; 1-2 мг марганца в день для дней 1-5 и 3,5-7 мкг селена в день для дней 1-5.
10. Комплект диет по п. 9, где рационы обеспечивают 2-4 мг витамина В1 в день для дней 1-5; 2-4 мг витамина В2 в день для дней 1-5; 20-30 мг витамина В3 в день для дней 1-5; 1-1,5 мг витамина В5 в день для дней 1-5; 2-4 мг витамина В6 в день для дней 1-5; 240-480 мкг витамина В9 в день для дней 1-5; 600-1000 МЕ витамина D в день для дней 1-5; 14-30 мг витамина Е в день для дней 1-5; более 80 мкг витамина К в день для дней 1-5; и 16-25 мкг витамина В12 на протяжении всего 5-дневного периода.
11. Комплект диет по п. 10, где рационы обеспечивают 600 мг докозагексаеновой кислоты (DHA, полученной из водорослей) на протяжении всего 5-дневного периода.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361841709P | 2013-07-01 | 2013-07-01 | |
| US61/841,709 | 2013-07-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016101047A Division RU2672594C2 (ru) | 2013-07-01 | 2014-07-01 | Состояние воздержания от пищи в качестве диетического лечения диабета |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018139711A true RU2018139711A (ru) | 2019-03-21 |
| RU2018139711A3 RU2018139711A3 (ru) | 2019-07-25 |
| RU2727960C2 RU2727960C2 (ru) | 2020-07-28 |
Family
ID=52115829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018139711A RU2727960C2 (ru) | 2013-07-01 | 2014-07-01 | Состояние воздержания от пищи в качестве диетического лечения диабета |
| RU2016101047A RU2672594C2 (ru) | 2013-07-01 | 2014-07-01 | Состояние воздержания от пищи в качестве диетического лечения диабета |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016101047A RU2672594C2 (ru) | 2013-07-01 | 2014-07-01 | Состояние воздержания от пищи в качестве диетического лечения диабета |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9386790B2 (ru) |
| EP (2) | EP3915399A1 (ru) |
| JP (3) | JP2016525091A (ru) |
| KR (1) | KR102410769B1 (ru) |
| CN (2) | CN105431055A (ru) |
| AU (2) | AU2014284399B2 (ru) |
| BR (2) | BR112015032889B1 (ru) |
| CA (1) | CA2916459C (ru) |
| DE (1) | DE202014011516U1 (ru) |
| MX (2) | MX381340B (ru) |
| NZ (1) | NZ715431A (ru) |
| RU (2) | RU2727960C2 (ru) |
| WO (1) | WO2015002972A1 (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102410769B1 (ko) * | 2013-07-01 | 2022-06-20 | 유니버시티 오브 써던 캘리포니아 | 당뇨병의 식이 요법으로서의 공복 상태 |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| MX2016012896A (es) | 2014-04-02 | 2017-05-12 | Univ Southern California | Autoinmunidad y tratamiento de la esclerosis multiple. |
| JP2018511625A (ja) * | 2015-04-16 | 2018-04-26 | ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ | 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食（ｆｍｄ）およびグルコース低下薬 |
| RU2724525C2 (ru) * | 2015-05-06 | 2020-06-23 | Юниверсити Оф Саутерн Калифорния | Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи |
| CA3009664C (en) * | 2016-01-12 | 2024-02-13 | University Of Southern California | Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers |
| MX2018009849A (es) | 2016-02-15 | 2018-11-09 | Univ Southern California | Combinaciones de farmacos y metodos para estimular regeneracion de tipo embrionaria para tratar diabetes y otras enfermedades. |
| AU2017261723B2 (en) | 2016-05-11 | 2023-02-09 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases. |
| IT201700008499A1 (it) * | 2017-01-26 | 2018-07-26 | Univ Degli Studi Genova | Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio |
| US11284640B2 (en) * | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| MX2020002638A (es) * | 2017-09-12 | 2020-07-13 | Nestle Sa | Metodos para imitar la restriccion calorica cronica y para impartir beneficios de salud a un animal. |
| WO2019178486A1 (en) | 2018-03-15 | 2019-09-19 | University Of Southern California | Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology |
| CN108719987A (zh) * | 2018-05-25 | 2018-11-02 | 生命说（北京）健康管理有限公司 | 一种全营养减肥食品及其制备方法 |
| US12304517B2 (en) | 2018-08-20 | 2025-05-20 | Indian Motorcycle International, LLC | Wheeled vehicle notification system and method |
| US11866042B2 (en) | 2018-08-20 | 2024-01-09 | Indian Motorcycle International, LLC | Wheeled vehicle adaptive speed control method and system |
| CN108812988A (zh) * | 2018-09-20 | 2018-11-16 | 江口县梵天红云茶业有限公司 | 一种白茶生产加工用翻炒装置 |
| CN113301807A (zh) * | 2018-11-09 | 2021-08-24 | L·纽乐股份有限公司 | 间歇性禁食模仿的营养棒 |
| MX2021013377A (es) | 2019-04-30 | 2022-04-12 | Univ Southern California | Dieta que simula el ayuno (fmd) como una intervencion para la enfermedad de alzheimer (ad). |
| TW202227113A (zh) | 2020-12-01 | 2022-07-16 | 南加州州立大學 | 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活 |
| US11688507B2 (en) | 2020-12-29 | 2023-06-27 | Kpn Innovations, Llc. | Systems and methods for generating a metabolic dysfunction nourishment program |
| CN115617953A (zh) * | 2022-11-15 | 2023-01-17 | 成都九洲电子信息系统股份有限公司 | 一种网络业务链路故障智能诊断方法及系统 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1093486A (en) * | 1912-02-06 | 1914-04-14 | Harvey B Dick | Halter. |
| US5470839A (en) * | 1993-04-22 | 1995-11-28 | Clintec Nutrition Company | Enteral diet and method for providing nutrition to a diabetic |
| MY115050A (en) * | 1995-10-16 | 2003-03-31 | Mead Johnson Nutrition Co | Diabetic nutritional product having controlled absorption of carbohydrate |
| RU2147228C1 (ru) * | 1997-03-25 | 2000-04-10 | Гинзбург Михаил Моисеевич | Способ лечения ожирения |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US8821915B2 (en) * | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20050031671A1 (en) * | 2003-08-06 | 2005-02-10 | James Johnson | Weight management, longevity and health paradigm |
| US8142809B2 (en) * | 2004-08-25 | 2012-03-27 | Regent of the Univ. of Minnesota | Compositions and methods to lower glycohemoglobin levels |
| CN101175416A (zh) | 2005-04-06 | 2008-05-07 | 诺瓦提斯公司 | 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物 |
| US8821947B2 (en) | 2006-06-01 | 2014-09-02 | Howard W. Selby, III | Cholesterol-reducing diet |
| PL2156188T3 (pl) | 2007-03-28 | 2021-11-15 | University Of Southern California | Indukcja zróżnicowanej odporności na stres i jej zastosowania |
| US8865646B2 (en) | 2007-03-28 | 2014-10-21 | University Of South California | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| DE102009016119A1 (de) | 2009-04-03 | 2010-10-14 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie |
| US20110118528A1 (en) | 2009-10-22 | 2011-05-19 | University Of Southern California | Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment |
| JP2013525269A (ja) * | 2010-03-10 | 2013-06-20 | イノボバイオロジック， インコーポレイテッド | グルコマンナン、キサンタンガム、およびアルギネートを含む、代謝性障害の処置のための食品 |
| WO2011118528A1 (ja) * | 2010-03-26 | 2011-09-29 | アイシン・エィ・ダブリュ株式会社 | 動力伝達装置 |
| ES2632348T3 (es) | 2010-04-28 | 2017-09-12 | University Of Southern California | Déficit de receptores de la hormona del crecimiento como causa de una reducción significativa de la señalización pro-envejecimiento, del cáncer y de la diabetes |
| SG191048A1 (en) | 2010-12-06 | 2013-07-31 | Cure Cancer Worldwide Corp | Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer |
| US20130316948A1 (en) | 2011-02-08 | 2013-11-28 | University Of Southern California | Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
| AP4026A (en) * | 2011-07-13 | 2017-02-04 | Alltech Inc | Algal lipid compositions and methods of preparing and utilizing the same |
| WO2014066426A1 (en) | 2012-10-22 | 2014-05-01 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
| CN114236130A (zh) * | 2013-02-12 | 2022-03-25 | 南加利福尼亚大学 | 用于减轻年龄相关症状的膳食包装 |
| KR102410769B1 (ko) * | 2013-07-01 | 2022-06-20 | 유니버시티 오브 써던 캘리포니아 | 당뇨병의 식이 요법으로서의 공복 상태 |
-
2014
- 2014-07-01 KR KR1020167002588A patent/KR102410769B1/ko active Active
- 2014-07-01 US US14/320,996 patent/US9386790B2/en active Active
- 2014-07-01 AU AU2014284399A patent/AU2014284399B2/en active Active
- 2014-07-01 NZ NZ715431A patent/NZ715431A/en unknown
- 2014-07-01 BR BR112015032889-0A patent/BR112015032889B1/pt active IP Right Grant
- 2014-07-01 EP EP21181173.2A patent/EP3915399A1/en active Pending
- 2014-07-01 WO PCT/US2014/045090 patent/WO2015002972A1/en not_active Ceased
- 2014-07-01 JP JP2016524321A patent/JP2016525091A/ja active Pending
- 2014-07-01 MX MX2016000102A patent/MX381340B/es unknown
- 2014-07-01 EP EP14819530.8A patent/EP3016528A4/en not_active Ceased
- 2014-07-01 RU RU2018139711A patent/RU2727960C2/ru active
- 2014-07-01 RU RU2016101047A patent/RU2672594C2/ru active
- 2014-07-01 BR BR122021002040-0A patent/BR122021002040B1/pt active IP Right Grant
- 2014-07-01 CA CA2916459A patent/CA2916459C/en active Active
- 2014-07-01 DE DE202014011516.8U patent/DE202014011516U1/de not_active Expired - Lifetime
- 2014-07-01 CN CN201480037998.0A patent/CN105431055A/zh active Pending
- 2014-07-01 CN CN202111411418.8A patent/CN114052245A/zh active Pending
-
2015
- 2015-12-21 MX MX2021003370A patent/MX2021003370A/es unknown
-
2016
- 2016-07-07 US US15/204,156 patent/US10433576B2/en active Active
-
2018
- 2018-01-10 AU AU2018200207A patent/AU2018200207B2/en active Active
-
2019
- 2019-02-22 JP JP2019030105A patent/JP6895473B2/ja active Active
- 2019-10-03 US US16/592,299 patent/US10932486B2/en active Active
-
2021
- 2021-01-29 US US17/162,809 patent/US11992036B2/en active Active
- 2021-06-07 JP JP2021094925A patent/JP2021165272A/ja active Pending
-
2024
- 2024-05-07 US US18/657,307 patent/US20240298689A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018139711A (ru) | Состояние воздержания от пищи в качестве диетического лечения диабета | |
| Saunders et al. | Omega‐3 polyunsaturated fatty acids and vegetarian diets | |
| CA2877811C (en) | Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd) | |
| Singh | Essential fatty acids, DHA and human brain | |
| Khan et al. | Sunflower oil: Efficient oil source for human consumption | |
| Valentine et al. | Nutritional management of the breastfeeding dyad | |
| RU2018141475A (ru) | Способы и рационы для защиты от химической интоксикации и связанных с возрастом заболеваний | |
| Freeman | Omega-3 fatty acids in major depressive disorder. | |
| RU2016140158A (ru) | Лечение аутоиммунной реакции и рассеянного склероза | |
| US9480670B2 (en) | Reduction of risk of obesity | |
| da Silva et al. | Quail egg yolk (Coturnix coturnix japonica) enriched with omega-3 fatty acids | |
| RU2018141550A (ru) | Диета, имитирующая голодание (FMD), в качестве иммунорегуляторного лечения желудочно-кишечных аутоиммунных/воспалительных заболеваний | |
| AU2014253404A1 (en) | Infant formula with a low content of MCFAs in specific proportions and a relatively high content of unsaturated fatty acids, and its use in promoting the healthy establishment of cognitive function in infants | |
| RU2007147203A (ru) | Комбинированные питательные продукты | |
| RU2011128132A (ru) | Пищевые добавки для лиц в возрасте 50 лет и старше для повышения жизнеспособности, иммунитета, здоровья глаз и костей | |
| Borges et al. | Senegalese sole juveniles can cope with diets devoid of supplemental fish oil while preserving flesh nutritional value | |
| US20160044947A1 (en) | Infant formula with a low content of medium-chain fatty acids in specific proportions, and its use in promoting and/or ensuring a balanced growth in infants | |
| JP2019140952A5 (ja) | 経口栄養調整食品 | |
| Abozid et al. | Effect of omega 3 fatty acids family in human health | |
| Nandivada et al. | Role of parenteral lipid emulsions in the preterm infant | |
| US20220118041A1 (en) | Blend of Plant-Extracted Oils | |
| EP3131420B1 (en) | Health programming during pregnancy | |
| Frøyland et al. | Risk Assessment of “Other Substances”–Eicosapentaenoic Acid, Docosapentaenoic Acid and Docosahexaenoic Acid | |
| Mekala et al. | Foods for Muscle Growth | |
| De Stefano et al. | Exploring vegetarian diets: health benefits, nutritional considerations, and implications for athletic performance |